53 results for "Steven H Lin"

Proton beam radiotherapy for esophageal cancer: challenges and opportunities in the modern era

Vivek Verma; Steven H. Lin

Precision Radiation Oncology, Vol. 6 No. 3 · 2022 · English · DOAJ Scopus

Abstract As the NRG GI006 and PROTECT trials seek to confirm results of the first randomized trial supporting the utility of proton beam therapy for esophageal cancer, several outstanding questions are discussed in this review. First, the applicability/extrapolation of the existing randomized trial…

Prognostic and Predictive Value of FDG-PET as an Aid in Oesophageal Cancer Management

Mian Xi; Steven H. Lin

European Medical Journal Oncology, Vol. 5 No. 1 · 2017 · English · DOAJ

18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is widely used for cancer staging before treatment and detection of recurrence during post-treatment surveillance. It is increasingly being recognised that tumour FDG uptake values may not only be prognostic, but could have predictive…

Evaluating Factors for Prophylactic Feeding Tube Placement in Gastroesophageal Cancer Patients Undergoing Chemoradiotherapy

Vivek Verma; Pamela K. Allen; Steven H. Lin

Frontiers in Oncology, Vol. 7 · 2017 · English · DOAJ Scopus

PurposeThough better studied in head/neck cancers, there are currently no studies on timing of feeding tube (FT) placement in patients with gastroesophageal cancer. This study sought to discern characteristics of patients who used versus did not use a prophylactic FT (pFT), and also analyzed…

866 The effect of butyrophilin 1A1 blockade in combination with radiation treatment in colon and Lewis lung carcinoma

Nan Li; Steven H Lin; Stephen S Yoo

Journal for ImmunoTherapy of Cancer, Vol. 11 No. Suppl 1 · 2023 · English · DOAJ Scopus

Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions

Yifan Wang; Weiye Deng; Nan Li et al.

Frontiers in Pharmacology, Vol. 9 · 2018 · English · DOAJ Scopus

Since the approval of anti-CTLA4 therapy (ipilimumab) for late-stage melanoma in 2011, the development of anticancer immunotherapy agents has thrived. The success of many immune-checkpoint inhibitors has drastically changed the landscape of cancer treatment. For some types of cancer, monotherapy…

Plasmonic nano-aperture label-free imaging (PANORAMA)

Nareg Ohannesian; Ibrahim Misbah; Steven H. Lin et al.

Nature Communications, Vol. 11 No. 1 · 2020 · English · DOAJ Scopus

Here, the authors report on an imaging method based on localized surface plasmon resonance excitation, employing gold nanodisk arrays as substrates that enable imaging of transparent dielectric particles of several sizes. They demonstrate the ability to detect and image particles smaller than the…

On target methods to induce abscopal phenomenon for Off‐Target effects: From happenstance to happenings

Blessie Elizabeth Nelson; Jacob J. Adashek; Steven H. Lin et al.

Cancer Medicine, Vol. 12 No. 6 · 2023 · English · DOAJ Scopus

Abstract Although the “abscopal phenomenon” has been described several decades ago, this phenomenon lately has been obtaining momentous traction with the dawn of immune‐based therapies. There has been increased cross talk among radiation oncologists, oncologists and immunologists and consequently a…

Clinical outcomes of intensity modulated proton therapy and concurrent chemotherapy in esophageal carcinoma: a single institutional experience

Anussara Prayongrat, MD; Cai Xu, MD; Heng Li, PhD et al.

Advances in Radiation Oncology, Vol. 2 No. 3 · 2017 · English · DOAJ Scopus

Purpose: Intensity-modulated proton therapy (IMPT) is an emerging advanced radiation technique. Although dosimetric studies demonstrate the superiority of IMPT for improving target conformity and reducing unnecessary dose to critical normal tissues, clinical experience is limited. We aim to…

1415 Thoracic FLASH radiotherapy significantly spares peripheral blood lymphocytes and improves proliferation of bone marrow stem/progenitor cells and lymphopenia recovery

Steven H Lin; Kevin Liu; Rong-Hua Tao et al.

Journal for ImmunoTherapy of Cancer, Vol. 11 No. Suppl 1 · 2023 · English · DOAJ Scopus

Editorial: Updates on radiation-induced lymphopenia

Pim J. J. Damen; Steven H. Lin; Peter S. N. van Rossum

Frontiers in Oncology, Vol. 14 · 2024 · English · DOAJ Scopus

Outcomes of re-irradiation for brain recurrence after prophylactic or therapeutic whole-brain irradiation for small cell lung Cancer: a retrospective analysis

Ryoko Suzuki; Xiong Wei; Pamela K. Allen et al.

Radiation Oncology, Vol. 13 No. 1 · 2018 · English · DOAJ Scopus

Abstract Background Small cell lung cancer (SCLC) can recur in the brain after whole-brain irradiation (WBI). We documented outcomes after treatment of such recurrences and sought predictors of local control and overall survival (OS). Materials and methods Eighty-five patients with SCLC and brain…

Heart and lung doses are independent predictors of overall survival in esophageal cancer after chemoradiotherapy

Cai Xu; Lanwei Guo; Zhongxing Liao et al.

Clinical and Translational Radiation Oncology, Vol. 17 · 2019 · English · DOAJ Scopus

Purpose: To analyze associations between heart and lung dose and overall survival (OS) in patients with esophageal cancer who received concurrent chemo-radiotherapy (CCRT) with or without surgery. Patients and methods: Patients received intensity-modulated radiation therapy (median dose 50.4 Gy)…

BTN1A1 is a novel immune checkpoint mutually exclusive to PD-L1

Young-Seung Kim; Bong-Ki Hong; Steven H Lin et al.

Journal for ImmunoTherapy of Cancer, Vol. 12 No. 3 · 2024 · English · DOAJ Scopus

Background While Programmed cell death protein 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) blockade is a potent antitumor treatment strategy, it is effective in only limited subsets of patients with cancer, emphasizing the need for the identification of additional immune checkpoints…

732 Immune activation with plinabulin enhances anti-tumor response combining radiation with immune checkpoint blockade

Vivek Subbiah; Huiying Sun; Siqing Fu et al.

Journal for ImmunoTherapy of Cancer, Vol. 11 No. Suppl 1 · 2023 · English · DOAJ Scopus

Lymphocyte Depletion Rate as a Biomarker of Radiation Dose to Circulating Lymphocytes During Fractionated Partial-Body Radiation Therapy

Susannah G. Ellsworth, MD; Anirudh Yalamanchali, MD; Tim Lautenschlaeger, MD, PhD et al.

Advances in Radiation Oncology, Vol. 7 No. 5 · 2022 · English · DOAJ Scopus

Purpose: Radiation causes exponential depletion of circulating lymphocyte populations; in turn, radiation-induced lymphopenia is associated with worse survival for many solid tumors, possibly owing to attenuated antitumor immune responses. Identifying reliable and reproducible methods of…

Radiation-Induced Lymphopenia Risks of Photon Versus Proton Therapy for Esophageal Cancer Patients

Saba Ebrahimi, BSc; Gino Lim, PhD; Amy Liu, MSc et al.

International Journal of Particle Therapy, Vol. 8 No. 2 · 2021 · English · DOAJ Scopus

Purpose: To assess possible differences in radiation-induced lymphocyte depletion for esophageal cancer patients being treated with the following 3 treatment modalities: intensity-modulated radiation therapy (IMRT), passive scattering proton therapy (PSPT), and intensity-modulated proton therapy…

Radiation-Induced Lymphopenia is a Causal Mediator of Survival After Chemoradiation Therapy for Esophagus Cancer

Yiqing Chen, MSc; Yan Chu, PhD; Peter S.N. van Rossum, MD, PhD et al.

Advances in Radiation Oncology, Vol. 9 No. 10 · 2024 · English · DOAJ Scopus

Purpose: Radiation-induced lymphopenia (RIL) is common during chemoradiation therapy. Severe lymphopenia is associated with reduced survival. Proton beam therapy (PBT), with its substantially more compact dose distributions, spares circulating lymphocytes and immune organs at risk to a greater…

Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy

Ying Jing; Jin Liu; Youqiong Ye et al.

Nature Communications, Vol. 11 No. 1 · 2020 · English · DOAJ Scopus

Immunotherapy, the reactivation of the immune system to recognize cancer cells, can be accompanied by severe adverse effects. Here, the authors use pharmacovigilance and genomic data to be able to predict which patients might be susceptible to such severe events.

Dosimetric and clinical outcomes after volumetric modulated arc therapy for carcinoma of the thoracic esophagus

Cai Xu, MD; Mian Xi, MD; Ritsuko Komaki, MD et al.

Advances in Radiation Oncology, Vol. 2 No. 3 · 2017 · English · DOAJ Scopus

Purpose: The efficiency of radiation delivery via volumetric modulated arc therapy (VMAT) is indisputable, but outcomes after VMAT for thoracic esophageal carcinoma are largely unknown. Methods and materials: We retrospectively analyzed 65 patients with thoracic esophageal cancer who received VMAT…

Prognosis of severe lymphopenia after postoperative radiotherapy in non-small cell lung cancer: Results of a long-term follow up study

Wang Jing; Yufei Liu; Hui Zhu et al.

Clinical and Translational Radiation Oncology, Vol. 28 · 2021 · English · DOAJ Scopus

Purpose: To investigate the incidence and prognosis of severe radiation-induced lymphopenia (sRIL) after postoperative radiotherapy (PORT) for resected NSCLC. Patients and methods: Between 1998 and 2017, 170 patients treated with PORT for NSCLC were retrospectively reviewed. Lymphopenia was divided…